Transcriptomic Analysis of Metastatic Uveal Melanoma and Differences in Male and Female Patients

被引:0
|
作者
Doddi, Sishir [1 ]
Hamoud, Abdul-Rizaq [1 ]
Eby, Hunter M. [1 ]
Zhang, Xiaolu [1 ]
Imami, Ali Sajid [1 ]
Shedroff, Elizabeth [1 ]
Schiefer, Isaac [2 ]
Moreno-Lopez, Jose [2 ]
Gamm, David [3 ,4 ]
Meller, Jaroslaw [5 ]
Mccullumsmith, Robert E. [1 ,6 ]
机构
[1] Univ Toledo, Coll Med, Dept Neurosci, 2801 W Bancroft St, Toledo, OH 43606 USA
[2] Univ Toledo, Coll Pharm & Pharmaceut Sci, Dept Med & Biol Chem, Toledo, OH 43606 USA
[3] Univ Wisconsin, McPherson Eye Res Inst, Madison, WI USA
[4] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA
[5] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA
[6] Promedica, Neurosci Inst, Toledo, OH USA
关键词
Metastasis; melanoma; uvea; RNA Seq; bioinformatics; SET ENRICHMENT ANALYSIS; EXPRESSION; GROWTH;
D O I
10.21873/cgp.20452
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Uveal melanoma is an ocular malignancy whose prognosis severely worsens following metastasis. In order to improve the understanding of molecular physiology of metastatic uveal melanoma, we identified genes and pathways implicated in metastatic vs non-metastatic uveal melanoma. Patients and methods: A previously published dataset from Gene Expression Omnibus (GEO) was used to identify differentially expressed genes between metastatic and non-metastatic samples as well as to conduct pathway and perturbagen analyses using Gene Set Enrichment Analysis (GSEA), EnrichR, and iLINCS. Results: In male metastatic uveal melanoma samples, the gene LOC401052 is significantly down-regulated and FHDC1 is significantly up-regulated compared to non-metastatic male samples. In female samples, no significant differently expressed genes were found. Additionally, we identified many significant up-regulated immune response pathways in male metastatic uveal melanoma, including "T cell activation in immune response". In contrast, many top up-regulated female pathways involve iron metabolism, including "heme biosynthetic process". iLINCS perturbagen analysis identified that both male and female samples have similar discordant activity with growth factor receptors, but only female samples have discordant activity with progesterone receptor agonists. Conclusion: Our results from analyzing genes, pathways, and perturbagens demonstrate differences in metastatic processes between sexes.
引用
收藏
页码:350 / 360
页数:11
相关论文
共 50 条
  • [41] Proteomics of Metastatic and Non-Metastatic Uveal Melanoma
    Crabb, John W.
    Crabb, Jack S.
    Jang, Geeng-Fu
    Willard, Belinda
    Hu, Bo
    Kalirai, Helen
    Singh, Arun D.
    Coupland, Sarah E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [42] Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy
    Danielli, R.
    Queirolo, P.
    Testori, A.
    Plummer, R.
    Razi, E.
    Sileni, V. Chiarion
    Calabro, L.
    Di Giacomo, A. M.
    Ridolfi, R.
    Maio, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 581 - 581
  • [43] Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
    Riccardo Danielli
    Ruggero Ridolfi
    Vanna Chiarion-Sileni
    Paola Queirolo
    Alessandro Testori
    Ruth Plummer
    Monica Boitano
    Luana Calabrò
    Costanza De Rossi
    Anna Maria Di Giacomo
    Pier Francesco Ferrucci
    Laura Ridolfi
    Maresa Altomonte
    Clelia Miracco
    Angelo Balestrazzi
    Michele Maio
    Cancer Immunology, Immunotherapy, 2012, 61 : 41 - 48
  • [44] Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma
    Alexander, Marliese
    Mellor, James D.
    McArthur, Grant
    Kee, Damien
    MEDICAL JOURNAL OF AUSTRALIA, 2014, 201 (01) : 49 - 53
  • [45] Efficacy of MEK Inhibition with Trametinib as Monotherapy in Patients with metastatic Uveal Melanoma
    Peuker, C. A.
    Rohleder, E.
    Leyvraz, S.
    Rittig, S. M.
    Keller, U.
    Joussen, A. M.
    Keilholz, U.
    Ochsenreither, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 32 - 33
  • [46] Metastatic Uveal Melanoma: Case Reports of three Patients treated with Sorafenib
    Schenck, F.
    Renne, J.
    Krengel, S.
    Degen, A.
    Kapp, A.
    Becker, J. C.
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2010, 8 (09): : 762 - 762
  • [47] IPILIMUMAB IN PRETREATED METASTATIC UVEAL MELANOMA PATIENTS: SAFETY AND CLINICAL EFFICACY
    Danielli, Riccardo
    Queirolo, Paola
    Testori, Alessandro
    Plummer, Ruth
    Razis, Evangelia
    Sileni, Vanna Chiarion
    Calabro, Luana
    Di Giacomo, Anna Maria
    Ridolfi, Ruggero
    Maio, Michele
    ANNALS OF ONCOLOGY, 2009, 20
  • [48] Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
    Danielli, Riccardo
    Ridolfi, Ruggero
    Chiarion-Sileni, Vanna
    Queirolo, Paola
    Testori, Alessandro
    Plummer, Ruth
    Boitano, Monica
    Calabro, Luana
    De Rossi, Costanza
    Di Giacomo, Anna Maria
    Ferrucci, Pier Francesco
    Ridolfi, Laura
    Altomonte, Maresa
    Miracco, Clelia
    Balestrazzi, Angelo
    Maio, Michele
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (01) : 41 - 48
  • [49] Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients
    Grynberg, Shirly
    Stoff, Ronen
    Asher, Nethanel
    Shapira-Frommer, Ronnie
    Schachter, Jacob
    Haisraely, Ory
    Lawrence, Yaacov
    Ben-Betzalel, Guy
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [50] Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib
    Niederkorn, Anna
    Wackernagel, Werner
    Artl, Monika
    Schwantzer, Gerold
    Aigner, Birgit
    Richtig, Erika
    ACTA OPHTHALMOLOGICA, 2014, 92 (08) : e696 - e697